Yariv Gratz

Tel-Aviv University operates as a university in Israel. Its faculties include arts, engineering, science, humanities, law, life science, management, medicine, and social science. The company was founded in 1956 and is headquartered in Ramat Aviv, Israel.

Scientus Pharma, Inc. provides biopharmaceutical products extracted from the cannabis plant. The private company is based in Whitby, Canada.

JSB-Partners LP offers specialized investment banking and advisory services to biotechnology and pharmaceutical companies. Its services include product partnerships, mergers and acquisitions, private placements and public underwritings. The company was founded by Wolfgang Rudolph Ralph Stoiber in 1999 and is headquartered in Boston, MA.

Organovo, Inc. develops and supplies pharmaceutical products. It focuses on delivering human tissue printing technology and creating tissue on demand for research and surgical applications. The firm helps physicians and researchers fulfill the promise of regenerative medicine by overcoming problems in cardiovascular medicine, medical research and transplant medicine. The company was founded by Eric Michael David, Andras Forgacs, Gabor Forgacs and Keith Murphy in 2007 and is headquartered in San Diego, CA.

Immunic AG develops pharmaceuticals in the immunology space. The firm offers immune modulators to block TH17-and TH1-mediated immune and autoimmune responses. The company was founded by Andreas Muhler and Manfred Groppel in April 2016 and is headquartered in Martinsried, Germany.

Actavis Pharma, Inc. develops, manufactures, and markets pharmaceutical products. It offers solid dosage and sterile dosage generic products. The company is headquartered in Morristown, NJ.

The International Partnership for Microbicides develops products for the prevention of human immunodeficiency virus. The private company is based in Silver Spring, MD.

Barnev, Inc. is a healthcare information technology company specializing in the development, manufacturing, and marketing of comprehensive monitoring and information solutions to clinicians and hospitals for labor and delivery. The firm is the first to market with delivery suite/product solutions that improve the clinical management of patients, and improve economic efficiency for its customers. Its first product, the BirthTrack™ Continuous Labor Monitoring System, is the most exciting innovation in labor progression monitoring since the Friedman Labor Curve was introduced over 50 years ago. The BirthTrack System is a revolutionary continuous labor monitoring technology that provides obstetric caregivers invaluable, precise, objective, real-time information about the physical progress of labor.

Hazera Genetics is a world leader in the breeding, production and marketing of vegetable and field crop hybrid seeds. For more than Seventy years it has been utilizing responsible and conventional breeding methods to breed varieties having innovative traits and by doing so, it is constantly opening new horizons of growth and prosperity for growers and industrialists in all parts of the world. As an Israeli-based enterprise, not only that it benefits from direct access to Israel's world-famous agricultural expertise, but its close relationships with renowned local research institutions such as the Volcani Institute and the Hebrew University generate fruitful collaborative research ventures.

Part of Caesarstone Ltd., Caesarstone (UK) Ltd. is a British company that manufactures quartz surfaces. The company is based in Enfield, UK.

Pearl Cohen Zedek Latzer Baratz LLP is an international law firm engaging in the provision of legal services. Its practice areas include antitrust and competition, capital markets and securities, commercial litigation, cross border litigation, and startups. The company was founded by Zeev Pearl and is headquartered in Tel Aviv, Israel.

Abbott GmbH & Co. KG develops and manufactures health care products. It is engaged in the discovery, development, manufacture, and marketing of pharmaceutical, diagnostic, nutritional, and hospital products. It offers pharmaceutical and diagnostic products ranging from prevention and diagnosis to treatment and cure. The company is headquartered in Ludwigshafen, Germany.

Desert Research Institute Foundation supports environmental science research to maximize DRI's impact on improving people's lives. It offers research in atmospheric, earth and ecosystem sciences. The company was founded in 1982 and is headquartered in Las Vegas, NV.

Part of Ethypharm SAS, Altan Pharma Ltd. is an Irish company that develops, manufactures, and markets injectable medications. The company is based in Dublin, Ireland. The company was founded in 1998 by Guillermo A. Herrera. Guillermo A. Herrera has been the CEO since 1998. Altan Pharma was acquired by Ethypharm SAS from Malin Corp. Plc on October 01, 2021.

PanTheryx, Inc. operates as a medical nutrition company that researches, develops, and commercializes medical nutrition products targeting the gastrointestinal microbiome. The firm offers medical foods, food for special dietary use, and dietary supplements. The company was founded by Tim Starzland and Bimla Starzl in 2007 and is headquartered in Boulder, CO.

F3 Platform Biologics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel and practical biotechnology for human use. It handles research, clinical development, and commercialization of new indications surrounding amifostine, a compound that has been previously approved by FDA for indications involving the prevention and treatment of side effects related to cancer treatment and radiation therapy. The company was founded on June 5, 2018 and is headquartered in Atlanta, GA.

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multikinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization. In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award.